This dataset is the largest study to date of patients with mesothelioma treated with an anti–PD-1 or anti–PD-L1 antibody.
Raleigh, NC (PRWEB) June 10, 2016
A top mesothelioma researcher has presented study findings on the drug avelumab to a meeting of the nation’s cancer doctors. Those findings are the subject of a new article on the Surviving Mesothelioma website. Click here to read it now.
Avelumab is designed to inhibit an immune suppressing protein called PD-L1 which is expressed on the surface of mesothelioma cells. The study involved 53 patients with unresectable peritoneal or pleural mesothelioma.
“This dataset is the largest study to date of patients with mesothelioma treated with an anti–PD-1 or anti–PD-L1 antibody,” says Raffit Hassan, MD, of the National Cancer Institute. Dr. Hassan presented the findings earlier this week at the annual meeting of the American Society of Clinical Oncology in Chicago.
According to Dr. Hassan, the study found that avelumab produced a 56.6 percent overall disease control rate among the mesothelioma patients. Results were presented at the annual meeting of the American Society of Clinical Oncology in Chicago earlier this week.
“We are excited to bring the news about avelumab to our readers, especially in light of the limited effectiveness of standard cancer treatments in mesothelioma and the lack of second-line options,” says Alex Strauss, Managing Editor of Surviving Mesothelioma.
None of the mesothelioma patients died from treatment with avelumab, which was well-tolerated by most.
To read more about avelumab and the potential for PD-L1 inhibition in the treatment of mesothelioma tumors, see Investigational Mesothelioma Drug Produces Encouraging Results, now available on the Surviving Mesothelioma website.
Hassan, Raffit, et al, “Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.”, June 5, 2016, ASCO University website, http://meetinglibrary.asco.org/content/164219-176